EP3288537A1 - Process for producing polysaccharide microparticles for alveolar macrophage targeting, microparticles obtained therein and use thereof - Google Patents
Process for producing polysaccharide microparticles for alveolar macrophage targeting, microparticles obtained therein and use thereofInfo
- Publication number
- EP3288537A1 EP3288537A1 EP16729627.6A EP16729627A EP3288537A1 EP 3288537 A1 EP3288537 A1 EP 3288537A1 EP 16729627 A EP16729627 A EP 16729627A EP 3288537 A1 EP3288537 A1 EP 3288537A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- microparticles
- polysaccharide
- spray
- μπι
- drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011859 microparticle Substances 0.000 title claims abstract description 57
- 150000004676 glycans Chemical class 0.000 title claims abstract description 47
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 47
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 47
- 210000001132 alveolar macrophage Anatomy 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000008685 targeting Effects 0.000 title claims abstract description 19
- 230000008569 process Effects 0.000 title claims abstract description 15
- 238000001694 spray drying Methods 0.000 claims abstract description 22
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 12
- 239000000969 carrier Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 229920000161 Locust bean gum Polymers 0.000 claims description 21
- 235000010420 locust bean gum Nutrition 0.000 claims description 21
- 239000000711 locust bean gum Substances 0.000 claims description 21
- 229920002907 Guar gum Polymers 0.000 claims description 19
- 239000000665 guar gum Substances 0.000 claims description 19
- 235000010417 guar gum Nutrition 0.000 claims description 19
- 229960002154 guar gum Drugs 0.000 claims description 19
- 229920000855 Fucoidan Polymers 0.000 claims description 12
- 235000010418 carrageenan Nutrition 0.000 claims description 11
- 239000000679 carrageenan Substances 0.000 claims description 11
- 229920001525 carrageenan Polymers 0.000 claims description 11
- 229940113118 carrageenan Drugs 0.000 claims description 11
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 11
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 7
- 229920002581 Glucomannan Polymers 0.000 claims description 7
- 229940046240 glucomannan Drugs 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims description 4
- 229960003350 isoniazid Drugs 0.000 claims description 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 4
- 229960000885 rifabutin Drugs 0.000 claims description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 3
- 229960000633 dextran sulfate Drugs 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010031099 Mannose Receptor Proteins 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 229940124976 antitubercular drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- 229920002752 Konjac Polymers 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- -1 dextran sulfate Polymers 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 108010078070 scavenger receptors Proteins 0.000 description 2
- 102000014452 scavenger receptors Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000814 tuberculostatic agent Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Definitions
- the present invention relates to microencapsulation techniques of drugs, useful in the production of microparticles for the treatment of tuberculosis, using polysaccharide microparticles obtained by single step spray-drying.
- Alveolar macrophages are resident cells of the lung, particularly of the alveolar zone, being directly involved in the progress of some diseases, such as tuberculosis.
- macrophages host the bacteria responsible for the disease ⁇ Mycobacterium tuberculosis) and are therefore a privileged therapeutic target.
- any drug intended at macrophage targeting is required to reach this zone of the respiratory tract.
- Inhalation of drugs aimed at reaching the alveolar zone requires the design of specific carriers that are endowed with the adequate aerodynamic characteristics to enable the desired distribution within the lung. To permit so, an aerodynamic diameter of 0.5 - 3 ⁇ is usually the referred range.
- Polymeric microparticles are the carriers proposed more frequently for this objective of drug inhalation, because their aerodynamic properties can be tailored to fit specific requirements.
- Spray-drying is the most frequently used method to obtain microparticles.
- This is a microencapsulation technique known to produce microparticles with tunable properties depending on the optimisation of the parameters involved in the proper spray-drying procedure, thus fitting the need of permitting tuning the microparticles to exhibit specific characteristics.
- Macrophages exhibit several surface receptors that might be used to mediate targeting to these cells. Actually, these receptors are those involved in the recognition of pathogenic agents.
- the C-type lectin receptors and the scavenger receptors are the two families reported to be involved in most cases of polysaccharide recognition.
- the first family includes the mannose receptor, which has reported ability to recognise mannose, fucose, iV-acetylglucosamine and sulphated sugars, which are present in many polysaccharide substances.
- the second family has demonstrated affinity for several polysaccharides such as chondroitin sulphate, dextran sulphate and fucoidan, among others. This enhanced ability for recognition of certain units, makes the macrophages highly targetable with materials comprising these residues, namely polysaccharides.
- LAURIENZO P. Marine polysaccharides in pharmaceutical applications: an overview in Marine Drugs, 2010; 8 (9) : 2435-2465, describes that alginate microparticles permitted higher bioavailability and reduction of adverse effects when compared with the administration of antitubercular drugs in the free form.
- KUNDAWALA A. et al Preparation of Microparticles containing rifampicin as dry powder formulation: in vitro studies on aerossol performance in American Journal of Pharmtech Research 2(4), 2012, describe the production, by spray-drying, of a dry powder formulation of rifampicin consisting of chitosan microparticles, for an application in tuberculosis therapy.
- Figure 1 shows the microparticle morphology, observed by scanning electron microscopy (SEM) , wherein CRG denotes carrageenan, FUC denotes fucoidan, KGM denotes Konjac glucomannan, LBG denotes locust bean gum and GG denotes guar gum (partially hydrolysed) .
- SEM scanning electron microscopy
- Figure 2 shows comparative uptake of microparticles composed of different polysaccharides and polyvinyl alcohol (PVA, control), by NR8383 cells (rat alveolar macrophages), upon 2 hours exposure to 50 - 60 g/cm 2 of fluorescently-labelled microparticles (mean ⁇ SEM, n > 3), wherein CRG denotes carrageenan, FUC denotes fucoidan, denotes LBG denotes locust bean gum and GG denotes guar gum (partially hydrolysed) .
- CRG denotes carrageenan
- FUC denotes fucoidan
- LBG denotes locust bean gum
- GG denotes guar gum (partially hydrolysed) .
- the invention refers to microparticles produced by a single-step spray-drying process, which are based on selected polysaccharides regarding the objective of alveolar macrophage targeting.
- the parameters of the spray- drying process are optimised to permit the production of microparticles that evidence aerodynamic properties suitable to reach the alveolar zone, where alveolar macrophages reside.
- the microparticles are aimed at providing an inhalable strategy for tuberculosis therapy, thus requiring macrophage targeting.
- unloaded microparticles were produced and used.
- the present invention uses natural materials and, namely polysaccharides, which are absolutely advantageous, because if polysaccharides composed of the mentioned recognisable residues are used, it becomes possible producing targeted drug carriers in a single step, without the need to include targeting ligands at a posterior phase. Additionally, polysaccharides are obtained at a low cost, have high probability of evidencing biocompatibility and are very flexible structures.
- the strategy of designing polysaccharide carriers for inhalable tuberculosis therapy encompasses the single-step production of a carrier that naturally targets the macrophages.
- polysaccharides composing the microparticles were selected for their chemical structure, as this characteristic is the one specifically mediating the active targeting of macrophages.
- Selected polysaccharides include locust bean gum, guar gum, fucoidan, glucomannan, carrageenan, xanthan gum, glucan, dextran sulfate, chondroitin sulfate. All these polysaccharides bear in their structure, as natural components, chemical groups (namely sulphate) or residues (i.e.
- Locust bean gum is a galactomannan, having mannose and galactose residues in an average molar ratio of 4/1.
- Guar gum is a galactomannan, having mannose and galactose residues in an average molar ratio of 2/1.
- Fucoidan has fucose units in its structure and also sulfate groups.
- Glucomannan has glucose and mannose units in its structure, in a molar ratio of 1/1.6.
- the first step consists on the solubilisation of the polysaccharides.
- Each polysaccharide was used individually and the concentration of polymer varied within 1.5 and 2% (w/v) .
- the lower concentration mentioned (1.5%) was used when 2% was too viscous to enable spray-drying.
- Locust bean gum required grinding before solubilisation.
- Locust bean gum required heating at 85 °C for 30 minutes to solubilise.
- Carrageenan required heating at 50 °C for 30 minutes to solubilise.
- the spray-dryer was used in open mode configuration and compressed air was the applied gas.
- the spray-drying conditions were variable, depending on the material being used.
- the conditions were: inlet temperature between 140 °C and 180 °C, aspirator between 80% and 90%, solutions feed rate between 0.7 and 2 mL/min.
- microparticles either evidenced a spherical shape or a convoluted shape ( Figure 1) .
- Figure 1 microparticles of locust bean gum, guar gum, fucoidan, carrageenan and glucomannan were produced to demonstrate the concept.
- the characteristics of microparticles are summarised in Table 1. Feret diameters were determined to be between 1.4 and 1.8 ⁇ , while real densities ranged between 1.0 and 1.7 g/cm 3 , which resulted in theoretical aerodynamic diameters varying within 1.7 ⁇ and 2.3 ⁇ . Overall, the characteristics indicate the theoretical suitability for deep lung inhalation.
- microparticles were tested for their ability to encapsulate two different first-line antitubercular drugs in association, isoniazid and rifabutin, as required in tuberculosis therapy (single therapy is not recommended) .
- the encapsulation efficiencies varied between 74 and 89% for isoniazid, and 57 and 92% for rifabutin .
- the first object of the invention is a process for producing polysaccharide microparticles for alveolar macrophage targeting, using single step spray-drying, comprising : a) dissolving the polysaccharide in order to obtain a concentration of polymer between 1.5 and 2% (w/v) ;
- the polysaccharide is selected from the group consisting of locust bean gum, fucoidan, guar gum, carrageenan, glucomannan, xanthan gum, glucan, dextran sulfate and chondroitin sulfate.
- Particularly preferred polysaccharides are locust bean gum, fucoidan, guar gum and carrageenan.
- the spray-dryer is normally used in open mode configuration and the the gas applied by the spray-dryer is compressed air.
- the second object of the invention consists of polysaccharide microparticles for alveolar macrophage targeting, obtained by the process described above, having Feret diameters between 1.0 and 2.0 ⁇ , real densities between 1.0 and 1.7 g/cm 3 and theoretical aerodynamic diameters between 1.7 ⁇ and 2.3 ⁇ .
- the polysaccharide microparticles have Feret diameters between 1.4 and 1.8 ⁇ .
- the third object of the invention consists of such polysaccharide microparticles for use in the treatment of tuberculosis, as carriers for drugs used for treating such disease.
- One preferred drug combination is an association of isoniazid and rifabutin.
- Locust bean gum (LBG) microparticles 1 g of LBG is grinded in a mortar for 10 min, after which 5 mL HC1 0.1 M are added, while grinding continues until complete mixture of LBG and HC1. Purified water previously heated to 85 °C is then added, up to a final volume of 50 mL (LBG concentration is 2%, w/v) . The dispersion is maintained under magnetic stirring for 30 min and subsequently placed on a water bath at 85 °C under slow stirring for additional 30 min. At the end, the dispersion is kept under stirring at room temperature overnight, until the moment of spray- drying. Spray-drying operating parameters are: inlet temperature: 160 °C; aspirator: 85%; feed rate: 0.8 mL/min; and spray flow rate: 473 L/h. Microparticle production yield is 70%.
- GG microparticles 1 g of GG (partially hydrolysed) is dissolved in 50 mL of purified water under stirring for 20 min (GG concentration is 2%, w/v) . After dissolution, mannitol is added and dissolved in the GG solution to a final concentration of 0.5% (m/v) , in order to improve the final aerodynamic characteristics of the microparticles. The final solution is maintained under stirring for 20 min before spray-drying. Spray-drying operating parameters are: inlet temperature: 160 ⁇ 2 °C; aspirator: 80%; feed rate: 1.0 mL/min; and spray flow rate: 473 L/h. Microparticle production yield is 73%.
- KGM (partially hydrolysed) is dissolved in 50 mL of purified water, at 70 °C, under stirring for 45 min (KGM concentration is 2%, w/v) .
- Spray-drying operating parameters are: inlet temperature: 170 ⁇ 2 °C; aspirator: 90%; feed rate: 0.7 mL/min; and spray flow rate: 473 L/h. Microparticle production yield is 69%.
- THP-1 cells might be differentiated (using phorbolmyristate acetate, PMA) to exhibit macrophage phenotype and develop characteristics of alveolar macrophages.
- NR8383 cells are rat alveolar macrophages.
- Alveolar macrophages have scavenger receptors on the surface, including the mannose receptor (CD206) , reported as capable of recognising mannose, fucose units and sulphated sugars.
- CD206 mannose receptor
- the differentiation of THP-1 cells by ⁇ is reported to not induce these receptors, while they are described to be present in NR8383 cells. While all the selected polysaccharides display structural units capable of undergoing specific recognition by macrophages, polyvinyl alcohol (PVA) is devoid of such moieties and was used as control.
- PVA polyvinyl alcohol
- each polysaccharide was previously labelled with a fluorescent marker before the spray-drying process.
- Microparticles composing each formulation were insufflated over cell layers in 6-well plates and incubated for 2 hours. After that period, the cells were recovered and analysed by flow cytometry, to examine the compositions favouring macrophage capture .
- Locust bean gum, fucoidan, guar gum and carrageenan were the polysaccharides undergoing the experimental test of uptake, apart from the control PVA.
- Flow cytometry determines the number of macrophages in the sample and quantifies the amount of macrophages that exhibit fluorescence, which is a consequence of having phagocytosed microparticles that are fluorescently labelled.
- a control test was performed using non- fluorescent microparticles. In that case, no macrophages are detected as emitting a fluorescent signal or the detected signal is not significant (maximum obtained was 1%) .
- NR8383 cells give the most meaningful results, as this is the cell line exhibiting the receptor of interest.
- locust bean gum is the polymer showing higher affinity for macrophages, inducing 95% capture, followed by guar gum and carrageenan, which have a similar result (around 70% capture) .
- Curiously the uptake observed for fucoidan microparticles did not overpass 30%, inclusive remaining at a lower level comparing with the control PVA.
- the increase of the dose of contact to 220-250 g/cm 2 resulted in a general increase to values around 100% for all polysaccharides, indicating a dose-dependent effect (data not shown) .
- Locust bean gum, guar gum and the control PVA were also tested in macrophage-differentiated THP-1 cells at the concentration of 50-60 g/cm 2 , which resulted in an increase of capture to values around 90-100% in all cases, possibly as a consequence of the absence of the specific mannose receptor that could differentiate the uptake. This indicates that the presence of such receptor indeed enables a specific targeting .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a process for producing polysaccharide microparticles for alveolar macrophage targeting, using single step spray-drying. The presente invention also relates to the polysaccharide microparticles, obtained by the process of the invention, and to such polysaccharide microparticles for use in the treatment of tuberculosis, as carriers for drugs used for treating such disease.
Description
DESCRIPTION
"PROCESS FOR PRODUCING POLYSACCHARIDE MICROPARTICLES FOR ALVEOLAR MACROPHAGE TARGETING, MICROPARTICLES OBTAINED
THEREIN AND USE THEREOF"
FIELD OF THE INVENTION
The present invention relates to microencapsulation techniques of drugs, useful in the production of microparticles for the treatment of tuberculosis, using polysaccharide microparticles obtained by single step spray-drying.
BACKGROUND OF THE INVENTION
Alveolar macrophages are resident cells of the lung, particularly of the alveolar zone, being directly involved in the progress of some diseases, such as tuberculosis. In that case, macrophages host the bacteria responsible for the disease {Mycobacterium tuberculosis) and are therefore a privileged therapeutic target. As alveolar macrophages reside in the alveoli, any drug intended at macrophage targeting is required to reach this zone of the respiratory tract. Inhalation of drugs aimed at reaching the alveolar zone requires the design of specific carriers that are endowed with the adequate aerodynamic
characteristics to enable the desired distribution within the lung. To permit so, an aerodynamic diameter of 0.5 - 3 μπι is usually the referred range. Polymeric microparticles are the carriers proposed more frequently for this objective of drug inhalation, because their aerodynamic properties can be tailored to fit specific requirements. Spray-drying, in turn, is the most frequently used method to obtain microparticles. This is a microencapsulation technique known to produce microparticles with tunable properties depending on the optimisation of the parameters involved in the proper spray-drying procedure, thus fitting the need of permitting tuning the microparticles to exhibit specific characteristics. Macrophages exhibit several surface receptors that might be used to mediate targeting to these cells. Actually, these receptors are those involved in the recognition of pathogenic agents. Among the described receptors, the C-type lectin receptors and the scavenger receptors are the two families reported to be involved in most cases of polysaccharide recognition. The first family includes the mannose receptor, which has reported ability to recognise mannose, fucose, iV-acetylglucosamine and sulphated sugars, which are present in many polysaccharide substances. In turn, the second family has demonstrated affinity for several polysaccharides such as chondroitin sulphate, dextran sulphate and fucoidan, among others. This enhanced ability for recognition of certain units, makes the macrophages highly targetable with materials comprising these residues, namely polysaccharides.
Currently, carriers proposed for inhalable therapy of tuberculosis are usually devoid of specific targeting strategies and their application is only based on adequate aerodynamic properties and on the natural ability of macrophages for the unspecific phagocytosis of particulate matter. Approaches including active targeting abilities are based on the surface modification of preformed antitubercular drug-loaded carriers with mannose residues. Mannosylated carriers are, thus, the unique described as having specific targeting ability towards alveolar macrophages. The preformed carriers are frequently composed by synthetic polymers, namely polyesters, of which the most often used are polylactic (PLA) and poly (lactic- co-glycolic) acid (PLGA) .
GRENHA A. et al , Natural carriers for application in tuberculosis treatment in Journal of Microencapsulation: Micro and Nano Carriers, Volume 30, Issue 3, 2013, describe the usefulness of using alveolar macrophages as therapeutic target in antitubercular therapy. It is mentioned that nano and microparticles composed for instance of natural polymers, such as the polysaccharides chitosan or hyaluronic acid, could be used for this end.
LAURIENZO P., Marine polysaccharides in pharmaceutical applications: an overview in Marine Drugs, 2010; 8 (9) : 2435-2465, describes that alginate microparticles permitted higher bioavailability and
reduction of adverse effects when compared with the administration of antitubercular drugs in the free form.
KUNDAWALA A. et al , Preparation of Microparticles containing rifampicin as dry powder formulation: in vitro studies on aerossol performance in American Journal of Pharmtech Research 2(4), 2012, describe the production, by spray-drying, of a dry powder formulation of rifampicin consisting of chitosan microparticles, for an application in tuberculosis therapy.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the microparticle morphology, observed by scanning electron microscopy (SEM) , wherein CRG denotes carrageenan, FUC denotes fucoidan, KGM denotes Konjac glucomannan, LBG denotes locust bean gum and GG denotes guar gum (partially hydrolysed) . Figure 2 shows comparative uptake of microparticles composed of different polysaccharides and polyvinyl alcohol (PVA, control), by NR8383 cells (rat alveolar macrophages), upon 2 hours exposure to 50 - 60 g/cm2 of fluorescently-labelled microparticles (mean ± SEM, n > 3), wherein CRG denotes carrageenan, FUC denotes fucoidan, denotes LBG denotes locust bean gum and GG denotes guar gum (partially hydrolysed) .
SUMMARY OF THE INVENTION
The invention refers to microparticles produced by a single-step spray-drying process, which are based on selected polysaccharides regarding the objective of alveolar macrophage targeting. The parameters of the spray- drying process are optimised to permit the production of microparticles that evidence aerodynamic properties suitable to reach the alveolar zone, where alveolar macrophages reside. The microparticles are aimed at providing an inhalable strategy for tuberculosis therapy, thus requiring macrophage targeting. For the purpose of demonstrating the ability of the microparticles to target macrophages, unloaded microparticles were produced and used.
DE TAILED DESCRIPTION OF THE INVENTION
The present invention uses natural materials and, namely polysaccharides, which are absolutely advantageous, because if polysaccharides composed of the mentioned recognisable residues are used, it becomes possible producing targeted drug carriers in a single step, without the need to include targeting ligands at a posterior phase. Additionally, polysaccharides are obtained at a low cost, have high probability of evidencing biocompatibility and are very flexible structures. The strategy of designing polysaccharide carriers for inhalable tuberculosis therapy
encompasses the single-step production of a carrier that naturally targets the macrophages.
In the present invention, polysaccharides composing the microparticles were selected for their chemical structure, as this characteristic is the one specifically mediating the active targeting of macrophages. Selected polysaccharides include locust bean gum, guar gum, fucoidan, glucomannan, carrageenan, xanthan gum, glucan, dextran sulfate, chondroitin sulfate. All these polysaccharides bear in their structure, as natural components, chemical groups (namely sulphate) or residues (i.e. mannose, fucose, sulfate, iV-acetylglucosamine, galactose, etc) that are described to potentially undergo a direct recognition by alveolar macrophage surface receptors. The idea relying on this strategy of direct macrophage targeting was proven with some of the mentioned materials . Locust bean gum is a galactomannan, having mannose and galactose residues in an average molar ratio of 4/1.
Guar gum is a galactomannan, having mannose and galactose residues in an average molar ratio of 2/1.
Fucoidan has fucose units in its structure and also sulfate groups.
Glucomannan has glucose and mannose units in its structure, in a molar ratio of 1/1.6.
To produce the microparticles , the first step consists on the solubilisation of the polysaccharides. Each polysaccharide was used individually and the concentration of polymer varied within 1.5 and 2% (w/v) . The lower concentration mentioned (1.5%) was used when 2% was too viscous to enable spray-drying. These concentrations were found adequate to obtain microparticles with Feret ' s diameter around 1-2 μπι, which is known to favour macrophage capture. Several aspects required optimisation prior to spray-drying :
Locust bean gum required grinding before solubilisation.
Locust bean gum required heating at 85 °C for 30 minutes to solubilise.
Carrageenan required heating at 50 °C for 30 minutes to solubilise.
The spray-dryer was used in open mode configuration and compressed air was the applied gas. The spray-drying conditions were variable, depending on the material being used. For the set of specified polysaccharides the conditions were: inlet temperature between 140 °C and 180 °C, aspirator between 80% and 90%, solutions feed rate between 0.7 and 2 mL/min.
Depending on the selected matrix material
(polysaccharide) , the resulting microparticles either evidenced a spherical shape or a convoluted shape (Figure 1) . Of the set of polysaccharides mentioned above as possible materials, microparticles of locust bean gum, guar gum, fucoidan, carrageenan and glucomannan were produced to demonstrate the concept. The characteristics of microparticles are summarised in Table 1. Feret diameters were determined to be between 1.4 and 1.8 μπι, while real densities ranged between 1.0 and 1.7 g/cm3, which resulted in theoretical aerodynamic diameters varying within 1.7 μπι and 2.3 μπι. Overall, the characteristics indicate the theoretical suitability for deep lung inhalation.
Although not directly affecting the character of the invention, these microparticles were tested for their ability to encapsulate two different first-line antitubercular drugs in association, isoniazid and rifabutin, as required in tuberculosis therapy (single therapy is not recommended) . The encapsulation efficiencies varied between 74 and 89% for isoniazid, and 57 and 92% for rifabutin .
Objects of the Invention The first object of the invention is a process for producing polysaccharide microparticles for alveolar macrophage targeting, using single step spray-drying, comprising :
a) dissolving the polysaccharide in order to obtain a concentration of polymer between 1.5 and 2% (w/v) ;
b) spray-drying the obtained solution, in a single step, using the following spray-drying conditions:
i) inlet temperature between 140 °C and 180 °C,
ii) aspirator between 80% and 90%,
iii) solutions feed rate between 0.8 and 2 mL/min.
Preferably, the polysaccharide is selected from the group consisting of locust bean gum, fucoidan, guar gum, carrageenan, glucomannan, xanthan gum, glucan, dextran sulfate and chondroitin sulfate.
Particularly preferred polysaccharides are locust bean gum, fucoidan, guar gum and carrageenan.
The spray-dryer is normally used in open mode configuration and the the gas applied by the spray-dryer is compressed air.
The second object of the invention consists of polysaccharide microparticles for alveolar macrophage targeting, obtained by the process described above, having Feret diameters between 1.0 and 2.0 μπι, real densities between 1.0 and 1.7 g/cm3 and theoretical aerodynamic diameters between 1.7 μπι and 2.3 μπι.
Usually, the polysaccharide microparticles have Feret diameters between 1.4 and 1.8 μπι.
The third object of the invention consists of such polysaccharide microparticles for use in the treatment of tuberculosis, as carriers for drugs used for treating such disease.
One preferred drug combination is an association of isoniazid and rifabutin.
Preparation Examples
The following Examples are intended to illustrate the invention, but are not limitative of the scope of the invention, which is only determined by the contents of the claims .
Example 1
Locust bean gum (LBG) microparticles: 1 g of LBG is grinded in a mortar for 10 min, after which 5 mL HC1 0.1 M are added, while grinding continues until complete mixture of LBG and HC1. Purified water previously heated to 85 °C is then added, up to a final volume of 50 mL (LBG concentration is 2%, w/v) . The dispersion is maintained under magnetic stirring for 30 min and subsequently placed on a water bath at 85 °C under slow stirring for additional 30 min. At the end, the dispersion is kept under stirring at room temperature overnight, until the moment of spray- drying. Spray-drying operating parameters are: inlet temperature: 160 °C; aspirator: 85%; feed rate: 0.8 mL/min;
and spray flow rate: 473 L/h. Microparticle production yield is 70%.
Example 2
Guar gum (GG) microparticles: 1 g of GG (partially hydrolysed) is dissolved in 50 mL of purified water under stirring for 20 min (GG concentration is 2%, w/v) . After dissolution, mannitol is added and dissolved in the GG solution to a final concentration of 0.5% (m/v) , in order to improve the final aerodynamic characteristics of the microparticles. The final solution is maintained under stirring for 20 min before spray-drying. Spray-drying operating parameters are: inlet temperature: 160 ± 2 °C; aspirator: 80%; feed rate: 1.0 mL/min; and spray flow rate: 473 L/h. Microparticle production yield is 73%.
Example 3 Konjac glucomannan (KGM) microparticles: 1 g of
KGM (partially hydrolysed) is dissolved in 50 mL of purified water, at 70 °C, under stirring for 45 min (KGM concentration is 2%, w/v) . Spray-drying operating parameters are: inlet temperature: 170 ± 2 °C; aspirator: 90%; feed rate: 0.7 mL/min; and spray flow rate: 473 L/h. Microparticle production yield is 69%.
Characteristics of the Microparticles characteristics of polysaccharide-based
microparticles , in according to the invention, proposed to target alveolar macrophages in the ambit of tuberculosis therapy, are shown in Table 1.
Table 1
*Theoretical estimation (Aerodynamic diameter = Feret ' s diameter) x real density .
In vitro Assays
The proof-of-concept regarding the alveolar macrophage targeting ability was performed in vitro, using two cell culture models. Human THP-1 cells might be differentiated (using phorbolmyristate acetate, PMA) to exhibit macrophage phenotype and develop characteristics of alveolar macrophages. NR8383 cells are rat alveolar macrophages. Alveolar macrophages have scavenger receptors on the surface, including the mannose receptor (CD206) , reported as capable of recognising mannose, fucose units and sulphated sugars. The differentiation of THP-1 cells by
ΡΜΆ is reported to not induce these receptors, while they are described to be present in NR8383 cells. While all the selected polysaccharides display structural units capable of undergoing specific recognition by macrophages, polyvinyl alcohol (PVA) is devoid of such moieties and was used as control.
For the effects of this assay, which involves macrophage capture of the microparticles and a subsequent determination of the number of macrophages from a population that phagocytosed the microparticles, each polysaccharide was previously labelled with a fluorescent marker before the spray-drying process. Microparticles composing each formulation were insufflated over cell layers in 6-well plates and incubated for 2 hours. After that period, the cells were recovered and analysed by flow cytometry, to examine the compositions favouring macrophage capture . Locust bean gum, fucoidan, guar gum and carrageenan were the polysaccharides undergoing the experimental test of uptake, apart from the control PVA. Flow cytometry determines the number of macrophages in the sample and quantifies the amount of macrophages that exhibit fluorescence, which is a consequence of having phagocytosed microparticles that are fluorescently labelled. A control test was performed using non- fluorescent microparticles. In that case, no macrophages are detected as emitting a fluorescent signal or the
detected signal is not significant (maximum obtained was 1%) . NR8383 cells give the most meaningful results, as this is the cell line exhibiting the receptor of interest. As seen in Figure 2, upon the contact with a dose of 50-60 g/cm2 of microparticles of each polymer, locust bean gum is the polymer showing higher affinity for macrophages, inducing 95% capture, followed by guar gum and carrageenan, which have a similar result (around 70% capture) . Curiously the uptake observed for fucoidan microparticles did not overpass 30%, inclusive remaining at a lower level comparing with the control PVA. The increase of the dose of contact to 220-250 g/cm2 resulted in a general increase to values around 100% for all polysaccharides, indicating a dose-dependent effect (data not shown) . Locust bean gum, guar gum and the control PVA were also tested in macrophage-differentiated THP-1 cells at the concentration of 50-60 g/cm2, which resulted in an increase of capture to values around 90-100% in all cases, possibly as a consequence of the absence of the specific mannose receptor that could differentiate the uptake. This indicates that the presence of such receptor indeed enables a specific targeting .
The other polysaccharides that were indicated also hold the ability to potentiate phagocytosis, as they bear units potentially recognised by macrophage surface receptors .
Claims
1. A process for producing polysaccharide microparticles for alveolar macrophage targeting, using single step spray-drying, comprising:
a) dissolving the polysaccharide in order to obtain a concentration of polymer between 1.5 and 2% (w/v) ;
b) spray-drying the obtained solution, in a single step, using the following spray-drying conditions:
i) inlet temperature between 140 °C and 180 °C,
ii) aspirator between 80% and 90%,
iii) solutions feed rate between 0.8 and 2 mL/min.
2. The process according to claim 1, wherein the polysaccharide is selected from the group consisting of locust bean gum, fucoidan, guar gum, carrageenan, glucomannan, xanthan gum, glucan, dextran sulfate and chondroitin sulfate.
3. The process according to claim 2, wherein the polysaccharide is selected from the group consisting of locust bean gum, fucoidan, guar gum and carrageenan.
4. The process according to any one of claims 1 to 3, wherein the spray-dryer is used in open mode configuration .
5. The process according to any one of claims 1
to 4, wherein the gas applied by the spray-dryer is compressed air.
6. Polysaccharide microparticles for alveolar macrophage targeting, obtained by process of any one of claims 1 to 5, having Feret diameters between 1.0 and 2.0 μπι, real densities between 1.0 and 1.7 g/cm3 and theoretical aerodynamic diameters between 1.7 μπι and 2.3 μπι .
7. The polysaccharide microparticles according to claim 6, having Feret diameters between 1.4 and 1.8 μπι.
8. The polysaccharide microparticles according to claim 6 or 7, for use in the treatment of tuberculosis, as carriers for drugs used for treating such disease.
9. The polysaccharide microparticles for use according to claim 8, wherein the the drug is an association of isoniazid and rifabutin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT10841015 | 2015-04-29 | ||
PCT/IB2016/052353 WO2016174573A1 (en) | 2015-04-29 | 2016-04-26 | Process for producing polysaccharide microparticles for alveolar macrophage targeting, microparticles obtained therein and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3288537A1 true EP3288537A1 (en) | 2018-03-07 |
Family
ID=56132975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16729627.6A Withdrawn EP3288537A1 (en) | 2015-04-29 | 2016-04-26 | Process for producing polysaccharide microparticles for alveolar macrophage targeting, microparticles obtained therein and use thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3288537A1 (en) |
PT (1) | PT116887B (en) |
WO (1) | WO2016174573A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
WO2010007604A2 (en) * | 2008-07-16 | 2010-01-21 | Royal College Of Surgeons In Ireland | Inhalable microparticles, and methods for the production thereof |
-
2016
- 2016-04-26 WO PCT/IB2016/052353 patent/WO2016174573A1/en unknown
- 2016-04-26 EP EP16729627.6A patent/EP3288537A1/en not_active Withdrawn
- 2016-04-26 PT PT116887A patent/PT116887B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
PT116887A (en) | 2021-03-31 |
WO2016174573A1 (en) | 2016-11-03 |
PT116887B (en) | 2022-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Choukaife et al. | Alginate nanoformulation: Influence of process and selected variables | |
Arya et al. | Electrospraying: a facile technique for synthesis of chitosan‐based micro/nanospheres for drug delivery applications | |
Hou et al. | Preparation and characterization of novel drug-inserted-montmorillonite chitosan carriers for ocular drug delivery | |
Masalova et al. | Alginate and chitosan gel nanoparticles for efficient protein entrapment | |
Hussain et al. | Hyaluronic acid functionalized nanoparticles for simultaneous delivery of curcumin and resveratrol for management of chronic diabetic wounds: Fabrication, characterization, stability and in vitro release kinetics | |
Nayak | Tamarind seed polysaccharide-based multiple-unit systems for sustained drug release | |
Sun et al. | Preparation and characterization of porous biodegradable microspheres used for controlled protein delivery | |
Yang et al. | Dry powder inhaler formulation of lipid–polymer hybrid nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier particles | |
Grazia Cascone et al. | Poly (vinyl alcohol) hydrogels as hydrophilic matrices for the release of lipophilic drugs loaded in PLGA nanoparticles | |
Doan et al. | Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization | |
Chen et al. | Preparation of methotrexate-loaded, large, highly-porous PLLA microspheres by a high-voltage electrostatic antisolvent process | |
Wang et al. | Preparation of chitosan-based nanoparticles for delivery of low molecular weight heparin | |
Wang et al. | Dual-stage release of ketoprofen from electrosprayed core–shell hybrid polyvinyl pyrrolidone/ethyl cellulose nanoparticles | |
Thien | Electrospun chitosan/PVA nanofibers for drug delivery | |
WO2012160088A1 (en) | Bio-compatible nano and microparticles coated with stabilisers for pulmonary application | |
CN105749296A (en) | Ulcerative colitis tissue targeting molecule and application thereof | |
Jatal et al. | Lung targeted electrosprayed chitosan nanocomposite microparticles boost the cytotoxic activity of magnolol | |
WO2003062199A2 (en) | Pace-a microspheres for delivery of antigens | |
Rodriguez et al. | Effect of formulation and process parameters on chitosan microparticles prepared by an emulsion crosslinking technique | |
Ghasemishahrestani et al. | Tunable synthesis of gelatin nanoparticles employing sophorolipid and plant extract, a promising drug carrier | |
EP3288537A1 (en) | Process for producing polysaccharide microparticles for alveolar macrophage targeting, microparticles obtained therein and use thereof | |
Ahmady et al. | Alginate carrier as a controlled thymol delivery system: Effect of particle size | |
Lu et al. | Antheraea pernyi silk fibroin nanoparticles for drug delivery | |
Kaur et al. | Formulation and development of colon-targeted mucopenetrating metronidazole nanoparticles | |
Rodrigues et al. | Investigating the Effect of Chitosan’s Degree of Deacetylation on Size of the Nanoparticle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20171109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
110E | Request filed for conversion into a national patent application [according to art. 135 epc] |
Effective date: 20200122 |
|
18D | Application deemed to be withdrawn |
Effective date: 20191101 |